Published Feb. 14 & 21 (EPO & GB); Feb. 8 & 15 (WO)

Ajinomoto BCG immunogenic WO 96/04009

Tokyo vaccine

Fusion of the Mycobacterium bovis BCG a-antigen with a foreignantigen; for making an immunogenic vaccine.

Alabama, Univ. of Oxidative damage WO 96/04311

Birmingham, Ala. detection

Antibodies to nitrotyrosine; for detection of oxidative damage totissues.

American Cyanamid Cytomegalovirus WO 96/04383 &

Wayne, N.J. reduced MHC expression 04384

Identification of a human cytomegalovirus gene region involved indown-regulation of MHC class I gene expression.

Amgen Erythropoietin WO 96/03438

Thousand Oaks, Calif. receptor antibodies

Antibodies and fragments that activate the erythropoietin receptor,hybridomas; for erythropoiesis/treating anemia.

Anvret et al. Homologous WO 96/04397

Stockholm, Sweden recombination method

DNA-liposome preparation for gene transfection to replace mutantgenes by homologous recombination.

Baylor Coll. Med. Contraceptive WO 96/04310

Houston vaccines

Recombinant zona pellucida proteins with altered glycosylationpatterns, antibodies; for contraception.

Becton Dickinson Mycobacterial EPO 696 638

Franklin Lakes, N.J. lysis

One-step process for lysing mycobacteria; for DNA isolation andanalysis.

Boehringer Ingelheim Targeted WO 96/03517

Ingelheim, Germany transfection complex

Virus and viral vector preparation process for transfection usingpolycations and target cell ligands.

Boehringer Mannheim Interferon-inhibited EPO 696 639

Mannheim, Germany stem cells

Growth inhibition of hematopoietic stem cells using interferongamma; for protection during cytotoxic treatment.

Boehringer Mannheim Hepatitis C EPO 696 640

Mannheim, Germany antigen

Recombinant antigen from the NS3 region of hepatitis C; for animmunologic detection test (in German).

Cancer Res. Campaign Tech. Prodrug WO 96/03515

London cancer therapy

Cancer therapeutic comprising a vector capable of expressing anenzyme at the cell surface that can convert prodrugs.

Chiron Truncated hepatitis WO 96/04301

Emeryville, Calif. polypeptides

C-terminally truncated hepatitis C/E1/E2 polypeptides that removesmembrane-spanning region; for secretion.

Chiron Tissue WO 96/04377 & 040378

Emeryville, Calif. factor pathway inhibitor

Tissue factor pathway inhibitor, muteins, chimeric proteins, encodinggenes; for septic shock treatment.

Chiron Modified secreted WO 96/04382

Emeryville, Calif. viral proteins

Viral proteins modified to be secreted when expressed in productionhosts cells; for diagnostics and vaccines.

Ciba-Geigy Autoinhibitory WO 96/03501

Basel, Switzerland protein design

Determination of interactions between phosphatase/kinase andautoinhibitory polypeptides; for designing mimics.

Connaught Labs Hemagglutinin WO 96/03145

Swiftwater, Penn. conjugates

Conjugates of influenza hemagglutinin with a carrier; for making fluvaccines.

Connaught Labs Influenza WO 96/03506

Willowdale, Ont. Hin47 protein

Gene for analogues of influenza Hin47 protein, encoded protein withdecreased protease activity; for vaccines.

Demeter Biotech Ubiquitin- WO 96/03519 & 03522

Durham, N.C. lytic peptide fusions

Stabilized ubiquitin-lytic peptide fusion polypeptides, encodinggenes.

DGI Technologies Drug target WO 96/04557

Upper Montclair, N.J. antibodies

Antibodies to surface domain structure of pharmaceutical targets; fordesigning small molecule therapeutics.

Eisai Megakaryocyte WO 96/03434

Tokyo growth factor

Gene for megakaryocyte differentiation/proliferation factor, encodedprotein; for thrombocytopenia.

Gene Pharming Europe Collagen WO 96/03051

Leiden, Netherlands in milk

Collagen and procollagen transgenes; for creating transgenicmammals that secrete these proteins into their milk.

Genentech High-expressing WO 96/04391

S. San Francisco host cells

High-expressing host cell selection using a vector with marker andproduct gene controlled by same promoter.

Genetics Inst. Calcium-independent WO 96/03512

Cambridge, Mass. cytosolic phospholipase

Gene for calcium-independent cytosolic phospholipase A2/Benzyme, encoded protein; for screening anti-inflammatories.

German Res. Osteoclast- WO 96/04375

Ctr. Hlth. & Welfare modulating factors

Oberschleissheim, Germany

Osteoclast-modulating factor production from osteoinductive virus-infected osteoblast cells.

Green Cross Urinary trypsin WO 96/03503

Osaka, Japan inhibitor

Process for production of urinary trypsin inhibitor and its domains inyeast, genes, proteins, and expression vector.

Harvard Univ. Receptor-ligand WO 96/03499

Cambridge, Mass. assay

Receptor-ligand assay using the receptors and their genes to identifyunknown ligands and their genes.

Hoechst Laminin antibodies EPO 696 597

Frankfurt, Germany

Monoclonal antibodies against native laminin and the P1 domain (inGerman).

Human Genome Sciences Potassium WO 96/03415

Rockville, Md. channels

Genes for human potassium channels, encoded proteins; foridentifying agonists.

Innogenetics Phosphorylated WO 96/04309

Zwijnaarde, Netherlands tau antibodies

Monoclonal antibodies specific for phosphorylated tau protein; fordiagnosis of Alzheimer's disease.

Innogenetics Hepatitis C envelope WO 96/04385

Zwijnaarde, Netherlands proteins

Purified recombinant hepatitis C virus envelope proteins; for therapyand diagnosis.

INSERM (Natl. Inst. Non-linear WO 96/04374

Hlth. & Med. Res.) DNA/RNA oligo


Oligonucleotide that binds with non-linear DNA or RNA; forpreventing target sequence interaction.

Italian Natl. Res. Counc. Urokinase WO 96/03414

Rome, Italy receptor antisense oligos

Antisense oligos to human urokinase receptor; for treatment ofprimary and secondary cancers.

LTT Inst. Antiviral WO 96/03500

Kanagawa, Japan phosphorothioate oligos

Phosphorothioate oligos that have antiviral activity; for treatingherpes and HIV.

Lynxvale Herpes gene WO 96/04395

Cambridge, U.K. therapy vector

Herpes viral vector with inactivating mutations that reduceinfectivity; for gene therapy.

Magainin Pharma Biologically WO 96/04373

Plymouth Meeting, Penn. active fusions

E. coli hosts that express fusions between a carbohydrate bindingprotein and an amphiphilic peptide.

Mass. Gen. Hosp. HIV CD4 WO 96/03883

Boston decoy

Cells expressing the membrane-bound portion of the CD4 receptor;for treating HIV.

Mass. Gen. Hosp. Ikaros gene WO 96/04372

Boston transgenics

Transfected cells and transgenic animals containing the Ikaros gene.

MRC Phosphoglucomutase GB 2 292 219

(Med. Res. Counc.) polymorphisms


Human phosphoglucomutase-1 gene and protein polymorphisms; formaking detection test kits.

MRC Mutant herpes WO 96/03997

(Med. Res. Counc.) cancer therapy


Mutant herpes simplex viruses with non-functional genes; for cancertreatment.

MRC Herpes vaccine WO 96/04394

(Med. Res. Counc.) vector


Herpes simplex genome viral vector which has substantially lost itstransducing properties; for therapy/vaccination.

Merck Modified bradykinin WO 96/03495

Rahway, N.J. receptor transgenics

Gene for modified bradykinin B2 receptor; for introduction into anon-human host animal.

Merck Herpes muscle- WO 96/03510

Rahway, N.J. specific vaccine

Genes encoding herpes simplex 2 proteins cloned into vectors thatwill express in muscle cells; for vaccination.

NIH (Natl. Inst. Hlth.) Hepatitis A WO 96/04376

Bethesda, Md. virus receptor

Gene for hepatitis A virus receptor, encoded protein, transgenicanimals with gene; for screening assay and vaccines.

NIH (Natl. Inst. Hlth.) Chromatin WO 96/04390

Bethesda, Md. insulator element

DNA sequence that acts as a chromatin insulator element protectingexpressed genes from cis-acting regulation.

New York Univ. Fibrin-binding WO 96/04304

New York molecules

Genes for fibrin-binding molecules, encoded proteins; fordiagnosis/treatment of fibrin deposition diseases.

Oregon Reg. Primate Ctr. Bombesin-like WO 96/03416

Beaverton, Ore. peptide receptors

Genes for receptors for bombesin-like peptides, encoded receptors,antibodies; for screening assay.

Queensland Res. Inst. T cell WO 96/03144

Herston, Australia polypeptide vaccines

Cytotoxic T lymphocyte epitopes and encoding polynucleotides; formaking polypeptide vaccines.

Ramot Univ. Mucin-derived WO 96/03502

Tel Aviv, Israel cancer therapy

Mucin-derived proteins; for use as diagnostic and treatment agentsfor cancer.

Regeneron Pharma Receptor WO 96/04389

Tarrytown, N.Y. kinase/cytokine chimeras

Chimeric receptors consisting of extracellular receptor tyrosinekinases domains and cytoplasmic cytokine domains.

Rhone-Poulenc Rorer Topoisomerase WO 96/03516

Antony, France IV

Gene for topoisomerase IV, encoded protein, expression vector; forscreening modulators.

Rockefeller Univ. Obesity GB 2 292 382

New York polypeptides

Genes for obesity polypeptides, encoded proteins, expression vectors;for treating obesity.

Roussel Uclaf Apoptosis-inducing WO 96/04387

Romainville, France protease genes

Genes for polypeptides with protease and apoptosis-inducing activitythat are related to IL-1a converting enzyme.

Rutgers Univ. Brain-specific WO 96/03043

New Brunswick, N.J. kinase

Gene for human brain-specific kinase, encoded protein, antibodies,expression vector; for neurodegeneration.

Salk Inst. Acetylcholine-gated WO 96/03504

La Jolla, Calif. ion channel

Gene for acetylcholine-gated ion channel subunit, encoded protein;for identifying modulators.

SmithKline Beecham Inhibiting WO 96/04380 & 04381

Brentford, U.K. bacterial adhesion

Polypeptides from Staphylococcus aureus; for the prevention ofbacterial adhesion to extracellular matrix.

SmithKline Beecham IL-4 fusion WO 96/04388

Brentford, U.K. antagonist

IL-4 mutant or variant fused to a human immunoglobulin constantdomain or its fragment; for IL-4 antagonism.

Systemix Brain NCAM WO 96/04396

Palo Alto, Calif.

Neural cell adhesion molecule (NCAM) expressed only in braintissue, encoding gene, splice variants and encoded proteins.

Texas, Univ. of Bone/prostate WO 96/04379

Austin, Tex. growth factor

Gene for bone and prostate-derived growth factor, encoded protein.

Warner-Lambert Viral resistance WO 96/04386

Morris Plains, N.J. gene transfection

Introduction of transdominant negative retroviral integrase gene intomammalian cells; for viral resistance.

Yissum Res. & Develop. Temperature- WO 96/03521

Jerusalem controlled expression

Expression vector with promoter that causes increased transcriptionat lowered temperatures.

_ Compiled By Chester A. Bisbee

(c) 1997 American Health Consultants. All rights reserved.